Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.94 USD | -6.88% | -21.09% | -43.80% |
Financials (USD)
Sales 2024 * | 283M | Sales 2025 * | 382M | Capitalization | 515M |
---|---|---|---|---|---|
Net income 2024 * | -186M | Net income 2025 * | -101M | EV / Sales 2024 * | 3.08 x |
Net Debt 2024 * | 355M | Net Debt 2025 * | 281M | EV / Sales 2025 * | 2.08 x |
P/E ratio 2024 * |
-2.39
x | P/E ratio 2025 * |
-4.68
x | Employees | 597 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.57% |
Latest transcript on Revance Therapeutics, Inc.
1 day | -6.88% | ||
1 week | -21.09% | ||
Current month | -30.81% | ||
1 month | -11.15% | ||
3 months | -37.39% | ||
6 months | -70.42% | ||
Current year | -43.80% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Dustin Sjuts
PSD | President | 45 | 18-04-01 |
Tobin Schilke
DFI | Director of Finance/CFO | 49 | 18-11-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Angus C. Russell
CHM | Chairman | 68 | 11-02-28 |
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Jill Beraud
BRD | Director/Board Member | 63 | 19-06-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.18% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 464 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 4.94 | -6.88% | 2,846,679 |
24-03-15 | 5.305 | -2.30% | 1,885,482 |
24-03-14 | 5.43 | -9.80% | 1,915,010 |
24-03-13 | 6.02 | -4.22% | 1,511,625 |
24-03-12 | 6.285 | +0.40% | 1,828,988 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.80% | 515M | |
-2.61% | 88.56B | |
+13.03% | 45.79B | |
+36.31% | 22.19B | |
-17.46% | 16.82B | |
-13.08% | 15.81B | |
-8.68% | 12.87B | |
-2.24% | 12.94B | |
+0.30% | 8.71B | |
-8.54% | 8.78B |